What Mabion S.A. does

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) founded in 2007 and headquartered in Konstantynów Łódzki, Poland. The company provides end-to-end biologics development and manufacturing services to biopharmaceutical clients, spanning cell line development, process development, analytical services, drug substance manufacturing, and fill-finish for recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Manufacturing is based on mammalian cell culture using single-use bioreactor technology at 2000L–4000L commercial scale, with a planned upgrade to 8000L, operated across two GMP-certified facilities (a Research & Development Centre and a Research & Production Centre) built in part with over PLN 172M of EU/ERDF co-financing. Mabion is publicly listed on the Warsaw Stock Exchange (ticker: MAB) and serves a global client base across Europe, the Americas, and Brazil, with named customers including Novavax (vaccine manufacturing under a strategic cooperation extended through end-2029), Instituto de Biologia Molecular do Paraná (IBMP), Novalgen, and WPD Pharmaceuticals.

The company monetizes primarily through fee-for-service CDMO contracts and co-development partnerships, complemented by a selective proprietary pipeline of biosimilar and innovative biologic assets — most notably MabionCD20 (reactivated in 2026 for orphan disease indications under existing FDA Orphan Drug Designations for autoimmune hemolytic anemia and membranous nephropathy), plus the historical MabionHER2 and MabionEGFR programs. Its go-to-market model is direct enterprise field sales, supported by a Business Development team and newly appointed regional BD leadership for Europe (Nigel Stapleton) and North America (Marty Henehan); demand generation relies on industry conferences (BIO, CPHI, Bio-Europe, DCAT Week), scientific content marketing through its Science Hub, and direct outreach. Revenue mechanics are project-based and quote-based against enterprise biopharma clients.

Mabion's capital base is a mix of EU grants, public equity, and debt. Major shareholders include Twiti Investments Limited (11.87% of share capital, 14.17% of votes), the Maciej Wieczorek group (7.99% / 10.07%), and Polfarmex S.A. (9.12% / 11.04%), with the remainder widely held. The company secured an EBRD loan of approximately $15M in February 2023, bridge financing from Twiti in October 2025, and Japanese investor CBC Co., Ltd. debt in March 2026. Leadership was substantially refreshed in 2025 with the appointment of Gregor Kawaletz (ex-Catalent, Recipharm, NextPharma, IDT-Biologika, Albumedix) as CEO alongside other CXO hires from Janssen, J&J-Merck, and Biocon, positioning the company to execute on its Strategy 2025-2030 and its stated target of operational break-even by end-2026.

Name

Mabion S.A.

Legal name

Mabion S.A.

Website

https://mabion.eu

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Mabion S.A. is a Polish biopharmaceutical CDMO providing end-to-end biologics services — cell line development, process development, analytics, GMP drug substance, and fill-finish — to global biopharmaceutical clients using single-use mammalian cell culture technology at 2000L–4000L scale.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA), Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Biologics CDMO services
• Contract manufacturing organization
• Monoclonal antibody production
• Biosimilars development
• GMP drug substance manufacturing

Headquarters

HQ city

Konstantynów

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Mabion provides fee-for-service CDMO services to biopharmaceutical companies. Services span process development, analytics, drug substance manufacturing, and fill-finish for biologics including biosimilars, antibodies, ADCs, and recombinant proteins. Revenue is generated through project-based contracts with pharmaceutical clients.
2. Co-development Partnerships: Mabion engages in co-development partnerships where it contributes development and manufacturing expertise in exchange for development fees and potential milestone payments or royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics services spanning cell line development, process development, analytics, drug substance manufacturing, and fill-finish under GMP conditions. The company specializes in mammalian cell culture-based production of recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars, operating two modern facilities (Research & Development Centre and Research & Production Centre) in Konstantynów Łódzki, Poland, with single-use bioreactor capacity at the 2000L–4000L scale. In parallel, Mabion pursues proprietary innovative biologics programs such as MabionCD20 (an anti-CD20 monoclonal antibody with FDA Orphan Drug Designations) and co-development partnerships with biopharmaceutical clients worldwide.

Product overview

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) providing end-to-end biologics development and manufacturing services. The company operates two modern facilities—a Research&Development Centre and Research&Production Centre—specializing in sterile biotechnological products manufactured under GMP conditions using mammalian cell cultures. Mabion's service portfolio comprises CDMO Services (covering process development, analytics, and drug substance manufacturing), Co-Development Partnership Models (collaborative approaches replacing traditional contractor relationships), and Innovative Biologics programs including the MabionCD20 orphan drug asset. The company also offers specialized services in cell line development, ADC manufacturing, biosimilars, and clinical trial support through GLP-certified laboratories. Key partnerships include Novavax (vaccine manufacturing), Oddifact (AI-driven orphan drug development for MabionCD20), WPD Pharmaceuticals (ADC development), Celon Pharma (ADC products), and Sartorius (biopharmaceutical development cooperation).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• First and largest biopharmaceutical plant in the world operating in disposable technology
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Novavax, Inc.coreStrategic or Co-development Partner · 18 June 2026Mabion and Novavax have extended strategic cooperation for another three years until the end of 2029. Mabion provides contract manufacturing services for COVID-19 vaccine antigen production. The partnership has expanded to include analytical work for a combined influenza and COVID vaccine product. Novavax is a major customer driving significant revenue.
• Oddifact SAScoreStrategic or Co-development Partner · 17 June 2026French TechDev company Oddifact partnered with Mabion to explore MabionCD20 as a treatment for rare diseases using AI platform to identify orphan drug applications. This strategic pivot reopens the CD20 program previously developed as a rituximab biosimilar, now targeting the rare disease space through orphan drug designations.
• KriSan BiotechminorStrategic or Co-development Partner · 1 June 2026Mabion and KriSan Biotech signed Letter of Intent to explore ADC collaboration. The partnership aims to leverage combined expertise in antibody-drug conjugate development and manufacturing.
• WPD PharmaceuticalscoreStrategic or Co-development Partner · 12 March 2026Mabion and WPD Pharmaceuticals strengthened cooperation, planning joint development of innovative ADC molecules. Mabion completed analytical development project for WPD-401, delivering 20 analytical methods. Strategic collaboration in advanced conjugated oncology therapeutics.
• Celon Pharma S.A.minorStrategic or Co-development Partner · 13 January 2026Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products. Celon Pharma is also a founding shareholder of Mabion.
• SyVentominorStrategic or Co-development Partner · 15 December 2025Mabion and SyVento plan to begin cooperation in aseptic fill and finish of drug products. Partnership to expand service capabilities.
• NovalgencoreStrategic or Co-development Partner · 17 June 2025Mabion released first batch of Novalgen's next-generation T-cell engager, NVG-222, for first-in-human clinical trials. Demonstrates Mabion's capabilities in manufacturing novel T-cell engager molecules.
• Sartorius Stedim Cellca GmbHcoreTechnology or Integration · 14 April 2025Mabion and Sartorius announced strategic cooperation to advance biopharmaceutical development. Partnership includes commercializing services together and collaboration with IBMP on cell culture and process development.
• Instituto de Biologia Molecular do Paraná (IBMP)coreStrategic or Co-development Partner · 14 April 2025Mabion entered master agreement with IBMP for CDMO services in Brazil. Expanded cooperation with new orders under the framework agreement. Partnership supported by Sartorius collaboration.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Samsung Biologics: Large-scale mammalian CDMO offering process development, drug substance manufacturing, and fill-finish services to global biopharma. Comparable on core biologics CDMO offering, with significantly greater installed bioreactor capacity and global footprint.
• Lonza Group AG: Global leader in biologics CDMO services with mammalian cell culture manufacturing across multiple sites and large commercial-scale capacity. Directly comparable as a mammalian-cell-culture CDMO serving biopharma clients, though at materially larger scale and broader service portfolio.
• WuXi Biologics: End-to-end biologics CDMO providing cell line development, process development, and GMP manufacturing across multiple sites. Directly comparable end-to-end service model for mAbs and recombinant proteins, with substantially larger global scale.

Emerging players

• Alvotech: Iceland-headquartered biosimilars developer and manufacturer focused on mAb biosimilars with in-house manufacturing capability. Comparable as a competing biosimilars-focused player with proprietary products and CDMO-grade manufacturing capacity.

Direct peers

• Rentschler Biopharma: European-headquartered biologics CDMO focused on mammalian cell culture, offering cell line development through commercial manufacturing. Closely comparable on European footprint, mid-sized scale, and end-to-end service model.
• AGC Biologics: Mammalian and microbial CDMO offering cell line development, process development, analytics, and GMP manufacturing for mAbs, recombinant proteins, and complex modalities. Comparable on integrated biologics CDMO model and ability to serve clinical through commercial supply.
• mAbxience: European biologics CDMO and biosimilars developer offering mammalian cell culture development and manufacturing services. Comparable on biosimilars positioning, mammalian manufacturing capability, and mid-sized European CDMO profile.
• Polpharma Biologics: Polish-headquartered biologics CDMO and biosimilars developer with mammalian cell culture capabilities. Most direct European regional peer given shared Polish origin, focus on biosimilars, and biologics manufacturing service model.

Others

• Sartorius AG: Global supplier of bioprocessing equipment, single-use technologies, and process solutions for biologics manufacturing. Relevant as both Mabion's strategic technology partner and as a benchmark for the enabling technologies used in Mabion's facility.
• Celon Pharma S.A. Polish pharmaceutical company and founding shareholder of Mabion, now collaborating on ADC development. Comparable as a domestic Polish pharma partner and as an adjacent biologics developer, with a partial overlap on oncology pipeline ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabion S.A.